Recent Analysts’ Ratings Changes for Merit Medical Systems (MMSI)

Several brokerages have updated their recommendations and price targets on shares of Merit Medical Systems (NASDAQ: MMSI) in the last few weeks:

• 11/24/2025 – Merit Medical Systems had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Merit Medical Systems was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/17/2025 – Merit Medical Systems had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/14/2025 – Merit Medical Systems had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $106.00 price target on the stock.
• 11/14/2025 – Merit Medical Systems had its price target lowered by analysts at Canaccord Genuity Group Inc. from $104.00 to $93.00. They now have a “buy” rating on the stock.
• 11/14/2025 – Merit Medical Systems had its price target lowered by analysts at Wells Fargo & Company from $103.00 to $95.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – Merit Medical Systems had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/31/2025 – Merit Medical Systems had its price target raised by analysts at Barrington Research from $103.00 to $106.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – Merit Medical Systems was given a new $103.00 price target on by analysts at Robert W. Baird.
• 10/31/2025 – Merit Medical Systems had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $109.00 price target on the stock, up previously from $105.00.
• 10/31/2025 – Merit Medical Systems had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
• 10/17/2025 – Merit Medical Systems was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/16/2025 – Merit Medical Systems had its price target raised by analysts at Canaccord Genuity Group Inc. from $103.00 to $104.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Merit Medical Systems had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Merit Medical Systems had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $103.00 price target on the stock.

Insider Activity

In other news, Chairman Fred P. Lampropoulos sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $87.31, for a total transaction of $2,182,750.00. Following the transaction, the chairman owned 1,029,955 shares of the company’s stock, valued at approximately $89,925,371.05. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 60,000 shares of company stock worth $5,189,900 in the last ninety days. 3.20% of the stock is owned by insiders.

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.